Compare R & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | R | BLCO |
|---|---|---|
| Founded | 1933 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | R | BLCO |
|---|---|---|
| Price | $190.45 | $17.28 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 14 |
| Target Price | ★ $204.67 | $17.31 |
| AVG Volume (30 Days) | 323.2K | ★ 332.5K |
| Earning Date | 02-11-2026 | 02-18-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 10.62 | N/A |
| EPS | ★ 11.82 | N/A |
| Revenue | ★ $12,679,000,000.00 | $4,976,000,000.00 |
| Revenue This Year | $2.54 | $8.06 |
| Revenue Next Year | $3.60 | $5.79 |
| P/E Ratio | $16.10 | ★ N/A |
| Revenue Growth | 1.68 | ★ 6.23 |
| 52 Week Low | $125.54 | $10.45 |
| 52 Week High | $200.53 | $18.14 |
| Indicator | R | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 56.07 |
| Support Level | $189.37 | $17.18 |
| Resistance Level | $195.52 | $17.86 |
| Average True Range (ATR) | 4.72 | 0.42 |
| MACD | -0.69 | -0.02 |
| Stochastic Oscillator | 48.26 | 64.63 |
Ryder System Inc operates in three business segments: (1) Fleet Management Solutions which provides full-service leasing and leasing with flexible maintenance options, commercial rental and maintenance services of trucks, tractors and trailers to customers; (2) Supply Chain Solutions (SCS), which provides integrated logistics solutions, including distribution management, dedicated transportation, transportation management, brokerage, e-commerce, last mile, and professional services; and (3) Dedicated Transportation Solutions (DTS), which provides turnkey transportation solutions in the U.S., including dedicated vehicles, professional drivers, management, and administrative support.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.